Introduction
In chronic myelogenous leukemia (CML), the Bcr-Abl oncoprotein induces cell proliferation and protects cells from apoptosis (Wong and Witte, 2004) , and at more advanced stages of this leukemia, CML patients become relatively insensitive to therapy. The Bcr-Abl stimulates several signal transduction pathways (Puil et al., 1994; Ilaria et al., 1999; Klejman et al., 2002) , including the Jak2 pathway (Wilson-Rawls et al., 1996; Xie et al., 2001; Chu et al., 2004) . Bcr-Abl activates the Jak2 tyrosine kinase (Xie et al., 2001) , which is important for Bcr-Abl-mediated oncogenicity by enhancing expression of c-Myc (Xie et al., 2002) .
Imatinib mesylate (IM) is an effective inhibitor of the Bcr-Abl tyrosine kinase and is the first-line treatment of CML (Kantarjian et al., 2003; Chu et al., 2004) . However, in some CML patients, IM resistance develops. Thus, alternative drug targets need to be identified. We have shown that Jak2 is a critical target of Bcr-Abl tyrosine kinase. Importantly, Bcr-Abl is associated with a cluster of signaling proteins, including Jak2, Gab2, Akt and GSK3b. Inhibition of any of these signaling proteins affects the downstream targets by reducing c-Myc levels (Samanta et al., 2006) .
In accelerated and blast crisis phases of CML, BcrAbl þ cells become resistant to IM (Weisberg et al., 2005) . Hu et al. (2004) reported that in Bcr-Abl-induced B-lymphoblastic leukemia, Lyn is more important than in Bcr-Abl induced myeloid leukemia. Cells from CML myeloid blast crisis patients undergo 40-60% apoptosis after exposure to Lyn short interfering RNA (siRNA), whereas lymphoid blasts derived from CML blast crisis patients underwent a much higher induction of apoptosis (>90%) (Ptasznik et al., 2004) .
Treatment of CML patients with IM can also lead to IM resistance because of activation of Lyn/Hck tyrosine kinases; how Lyn kinase becomes activated is yet unknown (Dai et al., 2004; Bruno et al., 2007) . Lyn is reported to be involved in Bcr-Abl signaling and the oncoprotein activates Lyn (Nimmanapalli et al., 2002; Donato et al., 2003 Donato et al., , 2004 . Lyn is frequently over-expressed in blast crisis patients and its activation appears to be independent of Bcr-Abl (Donato et al., 2003) . Activated Lyn induces expression of antiapoptotic proteins Bcl-2 in CML (Dai et al., 2004) . In this type of IM resistance (O'Hare et al., 2006; Yokota et al., 2007) , Lyn kinase activity is considerably increased concomitant with the increase in cell survival (Bruno et al., 2007) . Dasatinib, a dual-kinase inhibitor (Bcr-Abl and Src/Lyn), is effective for treatment of many forms of IM resistance, including those caused by Lyn activation. However, Dasatinib, similar to all other second-generation tyrosine kinase inhibitors, is not effective against all the IM-resistant Bcr-Abl mutants, particularly the T315I BCR-ABL mutant (Alvarez et al., 2006; Yokota et al., 2007) . Although increased expression of Lyn with the progression of the disease is known, and Lyn is involved in the survival of CML cells, its exact position in the Bcr-Abl-driven signal transduction pathways, its downstream targets, its regulation by upstream regulators and the mechanism of continuous activation of Lyn in accelerated and blast crisis stages of CML are still unclear. The Donato group recently reported that in K562-R cells, Lyn is involved in a Bcr-Abl protein complex and its increased activity leads to CML disease progression during IM therapy (Wu et al., 2008) .
The Perrotti group has established that Bcr-Abl maintains its active tyrosine-phosphorylated form by inducing expression of SET, an inhibitor of PP2A, and that inhibition of PP2A activity diminishes Shp1 activity, a tyrosine phosphatase that dephosphorylates Bcr-Abl. Thus, SET suppresses the PP2A (serine/ threonine phosphatase) and Shp1 activities (Neviani et al., 2005; Perrotti and Neviani, 2006) . In this report, we have shown that Bcr-Abl does not directly activate expression of SET protein; rather Bcr-Abl activates Jak2, which in turn induces expression of SET, which then inhibits the PP2A-Shp1 phosphatase. As Lyn kinase is activated in some forms of IM-resistant CML, we questioned whether Lyn is involved in the Bcr-Ablinduced Jak2-mediated signaling pathway, and if so where Lyn is located in this signaling pathway, and what is the mechanism utilized by Bcr-Abl to regulate the Lyn tyrosine kinase. Here we show that Lyn is located downstream of Jak2 in the Bcr-Abl signaling pathway, and that Bcr-Abl utilizes Jak2 to activate the SET signaling loop (SET-PP2A-Shp1) for maintaining activated Lyn. Inhibition of Jak2 reduced the expression of SET, causing activation of PP2A and Ship1 phosphatases, which resulted in deactivation of Lyn, followed by induction of apoptosis.
Results
Initially we examined where Lyn is located in the Bcr-Abl signaling pathway. Then we explored how Lyn is regulated by its upstream or downstream regulators.
Knockdown of Jak2 inactivates Lyn tyrosine kinase
We knocked down Jak2 by transfection of Jak2-specific si-RNA in 32Dp210 cells and human CML BCR-ABL þ cell lines K562 and BV-173. At 72 h after transfection, cell lysates were analysed by western blotting using anti-Jak2 antibodies. The results showed that compared with the controls (not transfected), the level of Jak2 protein was significantly reduced ( Figure 1A , panels a-c). Jak1 and Jak3 proteins were not significantly reduced by Jak2 knockdown ( Figure 1D ). Blotting the same extract with anti-pLyn (pTyr 396) and anti-Lyn antibodies showed that the pTyr 396 Lyn level (the activated form of Lyn) was also significantly reduced, whereas the level of the Lyn protein was unchanged ( Figure 1A , panels a-c). These results indicate that Jak2 is upstream of the Lyn tyrosine kinase, and that Jak2 has an important role in maintaining Lyn in an activated state.
Downstream targets of Jak2 were dephosphorylated in cells transfected with si-RNA specific for Lyn To identify the downstream targets of Lyn, we transfected si-RNAs targeting Lyn into K562 cells. After 64 h, Lyn protein expression was down-regulated in the Lyn knockdown experiments ( Figure 1B , panels a and b), as were pTyr Gab2, pSer Akt, pSer GSK3 and c-Myc, but not pJak2 ( Figure 1B , panels a and c). These results indicate that Lyn kinase is required for the Jak2 signaling network that regulates pTyrGab2, pSerAkt and pSerGSK3 (Samanta et al., 2006) , and that these proteins are downstream of Lyn, and Lyn is downstream of Jak2 in the same Bcr-Abl/ Jak2 network. We suggest that Lyn directly phosphorylates Gab2 on YxxM residues, leading to activation of PI-3 kinase.
Lyn is also located downstream of Jak2 in imatinibresistant cells We have shown that IM-resistant BCR-ABL þ cells (BaF3 T315I and BaF3 E255K) underwent apoptosis on exposure to the Jak kinase inhibitor AG490, and that AG490 strongly inhibited the Bcr-Abl/Jak2 network (Samanta et al., 2006) . In order to confirm that Jak2 is involved in driving the same Bcr--Abl/Jak2 network in IM-resistant cells, we examined the signaling effects of Jak2-specific knockdown by Jak2 siRNA in IM-resistant BCR-ABL þ cell lines. BCR-ABL þ BaF3, T315I BCR-ABL þ BaF3 and E255K BCR-ABL þ BaF3 cells were transfected with Jak2 siRNA ( Figure 1C ) and non-targeted siRNA (data not shown). After 64 h, the Jak2 protein was reduced in both wild-type Bcr-Abl-expressing cells and in cells expressing the IM-resistant mutant forms of Bcr-Abl after Jak2 knockdown ( Figure 1C ). Importantly, pTyr 396 Lyn and other signaling molecules, including pAkt, and pGSK3b and c-Myc were considerably reduced in Jak2 knockdown cells compared with non-knockdown cells in the IM-resistant cells ( Figure 1C ).
Jak2 rescue experiment
The fact that Lyn is regulated by Jak2 was further shown by a rescue experiment. In these experiments, the Jak2-siRNA pool and Jak2-cDNA expression vectors were transfected separately and simultaneously. The results ( Figure 1E ) showed that down-regulation of pLyn (second lane from the left) was prevented in the presence of Jak2-cDNA expression vector (fifth lane from the left). The Jak2-siRNA pool used in this experiment was less efficient than the lot of Jak2-siRNA from Dharmacon Co. used in earlier experiments. This rescue experiment strongly supports that pLyn is downstream of Jak2 and Lyn activity is regulated by Jak2 ( Figure 1E ).
Chemical inhibitors of Jak2 strongly reduce the activation of Lyn kinase To confirm our findings with knockdown of Jak2, we examined the effects of several known Jak2 kinase inhibitors for their effects on activated Lyn kinase. Inhibition of Jak2 in 32Dp210 cells by the Jak2 inhibitor (TG101209) manufactured by TargeGen Inc. (San Diego, CA, USA; Pardanani et al., 2007; Pardanani, 2008) dramatically reduced levels of pTyr Jak2 (Tyr 1008) in 32Dp210 cells in a dose-dependent manner after 16 h ( Figure 2A, panel a) . Incubation of 32Dp210 cells with TG101209 also reduced levels of the activated Lyn kinase, confirming that Jak2 regulates the activity of Lyn kinase (Figure 2A, panel b) . TG101209 is 25-fold more potent for Jak2 inhibition than for Jak3. Moreover, TG101209 has no significant inhibitory effects on a variety of other kinases, including the Abl and Lyn kinases (Supplementary Table 2) .
We also tested the effects of two other Jak2 inhibitors on Lyn kinase activation. We utilized the Jak2 inhibitor AG490 in 32Dp210 cells treated for 7 h ( Figure 2B ), and showed that pLyn Tyr 396 was dramatically decreased in a dose-dependent manner. We immunoprecipitated Lyn and showed that pLyn Tyr 396 was also decreased at 50 and 100 mM concentrations of AG490 ( Figure 2C ). Of interest, an antibody to Jak2 co-precipitated Lyn and AG490 treatment drastically decreased the level of the doublet bands migrating at the size of Lyn ( Figure 2D ). These results indicate that Lyn is downstream of Jak2 and is physically associated with Jak2. At 16 h of treatment with these concentrations of AG490, cells were 85% viable after 16 h (Samanta et al., 2006) . We determined that AG490 treatment of BCR-ABL þ cells (K562 cells) increased levels of pTyr 507 Lyn and decreased levels of pTyr 396 (Supplementary Figure 1a and b), again confirming that Jak2 inhibition causes a decrease in activated Lyn levels in BCR-ABL þ cells. We also showed that AG490 inhibited tyrosine phosphorylation of Jak2 in a kinase assay (Supplementary Figure 1c , top panel) but had no effect on Lyn kinase activity (Supplementary Figure 1c , bottom panel). Similarly, AG490 had no effect on the activity of the Bcr-Abl kinase (not shown).
The Jak2 inhibitor 1,2,3,4,5,6-hexabromocyclohexane (HBC) (Sandberg et al., 2005) also decreased pTyr Lyn (396) in BCR-ABL þ 32Dp210 cells ( Figure 2E ) while at the same time increasing levels of pTyr 507 Lyn. The increase in the phosphorylation of Tyr 507 and decrease of pTyr 396 strongly indicate that Jak2 inhibition decreases the activity of Lyn kinase. We determined that HBC inhibited phosphorylation of Jak2 in 32Dp210 cells ( Figure 2E ) but had little effect on tyrosine phosphorylation of Jak1 and Jak3 (Supplementary Figure 1d ). HBC also had no effect on the Lyn kinase activity (Supplementary Figure 1e HBC treatment of 32Dp210 cells also decreased levels of pTyr (YxxM) of Gab2, consistent with our earlier findings indicating that activated Jak2 induces phosphorylation of Gab2 at YxxM sequences ( Figure 2E ). We have shown that inhibition of Jak2 by either Jak2-specific siRNA treatment or the Jak kinase inhibitor AG490 reduced levels of pTyr (YxxM) Gab2 (Samanta et al., 2006) . Gab2 is a major factor in the activation of the PI-3 kinase in Bcr-Abl þ cells (Sattler et al., 2002) . Thus, either Jak2 or an unknown tyrosine kinase downstream of Jak2 phosphorylates the YxxM sequence of Gab2. Based on our Lyn kinase knockdown experiments ( Figure 1B , panel a) and studies with Jak2 inhibitors (Figures 2A-E) , we believe that Lyn kinase is the kinase that phosphorylates the YxxM sequences in Gab2.
Jak2 inhibition reduced SET expression in IM-sensitive and resistant BCR-ABL þ cells Neviani et al. (2005) have shown that Bcr-Abl maintains its Tyr phosphorylated state by inducing SET, an inhibitor of the PP2A-Shp1 pathway. We determined whether Jak2 was involved in SET regulation, since BcrAbl is known to induce both SET expression (Li et al., 1996; Neviani et al., 2005; Perrotti and Neviani, 2006) and Jak2 activation. Transfection with Jak2-siRNA into imatinib-sensitive BCR-ABL þ K562 and BV-173 cells Jak2 regulates Lyn kinase AK Samanta et al reduced SET expression compared with the untreated control ( Figure 3A , panels a-c; and Supplementary  Figure 1f) . Treatment of BCR-ABL þ cells with Jak2 inhibitor (AG490) showed reduced expression of SET ( Figure 3A , panel d), and the TargeGen Jak2 inhibitor also inhibited SET protein expression ( Figure 3A , panel e). These findings indicate that the up-regulation of SET expression induced by BCR-ABL reported by Neviani et al. (2005) is in fact induced by the activated Jak2 tyrosine kinase in BCR-ABL þ cells.
Inhibition of Jak2 in Bcr-Abl þ mouse hematopoietic cells stimulates the levels of active PP2A PP2A is a serine/threonine phosphatase widely expressed in mammalian cells and is involved in controlling signal transduction by causing dephosphorylation of proteins on Ser/Thr residues. We hypothesize that Jak2 controls the activity of PP2A through its regulation of the SET protein. It is known that SET inhibits the function of PP2A in CML blast crisis cells (Neviani et al., 2005; Perrotti and Neviani, 2006) , We assayed PP2A activity after the inhibition of Jak2 using HBC ( Figure 3B ). For these experiments, we used a 32D cell clone expressing Bcr-Abl (b3a2), termed the 6-15 cell clone. The Jak2 inhibitor HBC was added for 2-8 h at doses of 25-100 mM. The level of PP2A activity in 32D cells was twice that of Bcr-Abl þ cells, as expected because increased SET expression in BcrAbl þ cells is inhibitory to PP2A. Inhibition of Jak2 by HBC greatly stimulated PP2A activity in Bcr-Abl þ cells in a dose-and time-dependent manner ( Figure 3B ), indicating Jak2 inhibited PP2A activity in CML cells.
Simultaneous inhibition of both Jak2 and PP2A enhances the dephosphorylation of tyrosine 396 of Lyn We speculated that PP2A might also have some role in dephosphorylation of tyrosine 396 of Lyn, as PP2A induces Bcr-Abl tyrosine dephosphorylation through the activation of tyrosine phosphatase Shp1 (Pathak and Yi, 2001) . In order to stimulate PP2A activity, we treated 32Dp210 cells with 40 mM forskolin, an enhancer of PP2A activity (Neviani et al., 2005) , for 1 h, followed by the addition of different amounts of Jak2 inhibitor AG490, and the incubation was continued for 16 h. Compared with Jak2 inhibition alone, phosphorylation of Lyn at Tyr 396 was significantly decreased in cells treated with both forskolin and the Jak2 inhibitor ( Figure 3C ). These results indicate that PP2A has an active role in the dephosphorylation of Tyr 396 of Lyn. To confirm this result, we pre-incubated 32Dp210 cells with okadaic acid (OA) to inhibit PP2A, (Neviani et al., 2005) and then incubated cells with different doses of Jak2 inhibitor AG490 as before and assayed the level pTyr 396 of Lyn. As expected, the phosphorylation of Tyr 396 of Lyn was increased in cells treated with both okadaic acid and the Jak2 inhibitor compared with treatment with the Jak2 inhibitor only ( Figure 3D ). These results indicate that PP2A has a role in regulating Lyn kinase activity in Bcr-Abl þ CML cells.
Inhibition of Jak2-induced expression of Shp1 correlates with decreased levels of pTyr 396 Lyn As the PP2A-induced inactivation of Bcr-Abl is mediated by Shp1 (Neviani et al., 2005) , we explored the involvement of Shp1 in the dephosphorylation of Tyr 396 of Lyn induced by Jak2 and Lyn kinase inhibition. To investigate this possibility, we treated BCR-ABL þ cells with different amounts of Jak2 inhibitor and examined the cell lysates for the level of Shp1 expression. Lysates were treated with different doses of Jak2 inhibitor HBC and analysed for Shp1 and pLyn Tyr 396 expression. pLyn Tyr 396 was reduced and Shp1 levels showed a corresponding increase (Figure 4a ). In addition, we used AG490 and lysates were used for immunoprecipitation with anti-Lyn and probed with anti-Shp1 and anti-Lyn antibody by western blotting. The results showed an association of Shp1 with Lyn, and Shp1 protein levels were increased in a dose-and time-dependent manner after treatment with the Jak2 inhibitor AG490 (Figures 4b and c) . Of interest, the increased Shp1 binding to Lyn kinase observed in IM-sensitive cells was also observed in IMresistant cells (not shown). These results indicate that Shp1 is associated with Lyn in the Bcr-Abl/Jak2/Lyn network, and that Shp1 has a role in regulating the level of pTyr 396 Lyn.
Inhibition of Shp1 blocks dephosphorylation of Tyr 396 of Lyn induced by Jak2 inhibition alone Sodium stibagluconate (SSG) is known to be a specific inhibitor of Shp1 (Pathak and Yi, 2001; Neviani et al., 2005; Yi et al., 2002) . To further assess the role of Shp1 in dephosphorylation of Lyn at tyrosine 396, we preincubated the 32Dp210 cells with SSG under different Jak2-inhibitory conditions and examined the level of dephosphorylation of Lyn at Tyr 396. The results showed that addition of AG490 alone caused a reduction of pTyr 396 Lyn levels (Figure 4d) . Addition of Shp1 inhibitor in the presence of AG490 increased the levels of pTyr 396 Lyn compared with AG490 alone (Figure 4d ). These results suggest that Shp1 action is required to decrease levels of pTyr 396 Lyn caused by Jak2 inhibition.
Jak2 inhibition reduced the oncogenic potential of Bcr-Abl þ cells Inhibition of Jak2 strongly inhibited colony formation of 32Dp210 cells in a dose-dependent manner (Table 1) . We noted the IC50 for reducing agar colony formation of 32Dp210 cells by AG490 was surprisingly low, about 4-5 mM instead of 100 mM for cells in culture. Similarly, HBC90 was also effective in preventing agar colony formation of 32Dp210 cells (Table 1) . AG490-mediated Jak2 inhibition also blocked soft agar colony formation by IM-resistant E255K and gatekeeper BCR-ABL mutant T315I (Supplementary Figure 2d and Table 1 ).
Jak2 inhibition induced apoptosis in IM-resistant Bcr-Abl þ BaF3 cells
We assessed whether the Jak2 inhibitors TG101209 and HBC induced apoptosis in the IM-sensitive and resistant cells. In IM-sensitive 32Dp210 and K562-R IM-resistant cells, TG101209 strongly induced apoptosis at concentrations of 1 mM or less (Figures 5a and b , left and right panels). Treatment of BaF3p210 cells with HBC induced apoptosis in X95% of the cells at 100 mM HBC after 48 h of treatment (Table 2 and Supplementary  Figure 2a) . Similar results were obtained with IM with X95% cells undergoing apoptosis at 5 mM (Supplementary Figure 2a) . In contrast, IM had little effect on both T315I and E225K mutants (Supplementary Figures 2b and c) as expected. These results indicate that inhibition of Jak2 is equally effective in the induction of apoptosis both in IM-sensitive and -resistant cells. treatment  2h  4h  6h  8h  2h  4h  6h  8h  2h  4h  6h  8h  2h  4h  6h  2h  4h  6h , c) show the expression level of Shp1 in 32Dp210 and K562 cells treated with AG490 in a dose-and time-dependent manner, respectively. For dose-dependent response, cell lysates were prepared after treating the cells with different amounts of AG490. For time-dependent experiments, 100 mM AG490 was incubated with the cells for 1-6 h. The cell-free lysates were prepared and anti-Lyn antibody was used to immunoprecipitate Lyn from the whole lysates. The immune complex was analysed by western blotting using anti-Shp1 and anti-Lyn antibodies. (d) Combined treatment with Shp1 tyrosine phosphatase inhibitor sodium stibagluconate and various doses of AG490 in 32Dp210 cells inhibited Lyn dephosphorylation more than AG490 treatment alone. 32Dp210 cells were treated with different amounts of AG490 in the presence (pre-incubated with 10 mM sodium stibagluconate for 1 h) and absence of sodium stibagluconate as indicated in the figure, and the incubation was continued for 16 h. The cells were harvested and cell-free detergent extract was analysed by western blotting using anti-pLyn (pTyr396) antibody. The membrane was also probed for b-actin to show the equal loading in all the lanes. Image quantification of pLyn was carried out by Image Quant software version 5.0. Jak2 regulates Lyn kinase AK Samanta et al from four patients who failed IM also responded to AG490 treatment. In contrast, hematopoietic progenitors from healthy donors were not significantly affected by treatment with AG490 (Figure 5d , Supplementary Table 1 ).
Jak2 inhibition induced apoptosis in cells from CML patients

Discussion
Jak2 inhibition by either Jak2 knockdown or use of various Jak2 inhibitors down-regulates Lyn kinase activity ( Figure 1 and Figure 2) . We have shown that activated Jak2 maintains high levels of phosphotyrosine Tyr 396 Lyn, the active form of the Lyn kinase, in BcrAbl þ cells through a pathway involving the induction of SET, which strongly inhibits activity of PP2A which then leads to down-regulation of Shp1 tyrosine phosphatase. Knockdown of Jak2 and treatment with Jak2 inhibitors reduced SET levels in CML cell lines and in mouse cell lines expressing IM-resistant forms of BcrAbl, indicating that activated Jak2 controls SET expression in all types of Bcr-Abl þ cells ( Figures 3A;  panels a and b) . Neviani et al. (2005) have already shown that SET which is overexpressed in solid tumors and leukemia is a target molecule of Bcr-Abl. SET mRNA is associated with hnRNP A1 in Ph þ cells and treatment of Bcr-Abl þ cells with imatinib reduced SET expression at both transcriptional and protein levels (Neviani et al., 2005) . As Jak2 is downstream of BcrAbl and inhibition of Jak2 by Jak2-siRNA or Jak2 inhibitors reduced SET expression considerably ( Figure 3A) , we anticipate that SET expression is being regulated by Jak2 by the same mechanism described for Bcr-Abl effects (transcriptional control) as reported by Neviani et al.
The involvement of activated PP2A in causing downregulation of active Lyn kinase was indicated by several types of experiments. First, an increase in PP2A activity was induced by Jak2 inhibition ( Figure 3B ). As SET expression does not occur in non-BCR-ABL cells (Neviani et al., 2005) , we did not observe changes in PP2A activity despite Jak2 inhibition in these nonleukemic cells, and PP2A activity was higher in non-BCR-ABL cells than in BCR-ABL þ cells ( Figure 3B ). Second, treatment with forskolin ( Figure 3C ) and butyryl forskolin (not shown), which have been shown to be activators of PP2A (Neviani et al., 2005) , in combination with Jak2 inhibition, decreased activated Lyn kinase levels more so than Jak2 inhibition alone, indicating that PP2A is involved in the inactivation of Lyn. In addition, inhibition of PP2A by treatment with okadaic acid combined with Jak2 inhibition increased the levels of Lyn kinase activity over and above that of Jak2 inhibition alone, again arguing that the Jak2 controls Lyn kinase activation through the PP2A-Shp1 pathway ( Figure 3D ). Third, combined inhibition of both Jak2 and Shp1 increased levels of activated Lyn kinase activation compared with Jak2 inhibition alone ( Figure 4D) .
One important question is whether pJak2 also activates Lyn kinase directly along with maintaining Lyn kinase activity. A number of potential Jak2 phosphorylation sites are present in Lyn kinase. They include amino acids 74-77, 172-175, 306-309 and 439-442 . Further studies are planned to answer this question.
Lyn is also present in the Bcr-Abl/Jak2 network complex, as Lyn is physically associated with Jak2 and SET, as suggested by co-immunoprecipitation of Lyn by anti-Jak2 antibody ( Figure 2D and Supplementary Figure 1f) . From our earlier studies (Samanta et al., 2006) and additional experiments presented here, our findings indicate that Bcr-Abl, Jak2, Lyn, Akt, GSK3 and SET are in a large network protein complex (Samanta and Arlinghaus, unpublished data) .
Our studies raise the possibility that IM resistance involving activated Lyn kinase might be overcome by Jak2 inhibition. In this regard, we find that both Jak2 Abbreviation: HBC, hexabromocyclohexane.
(a) 32Dp210, BaF3/p210, BaF3-T315I and BaF3/E255K cells were incubated in HBC during colony formation in soft agar using various doses of AG490 and for 32Dp210 cells with various doses of HBC. Quantitation of the effects is shown as percentage. (b) The effect of Jak2 inhibition by HBC on anchorage-independent growth of 32Dp210 cells.
inhibitors, AG490 and HBC, induced apoptosis at high levels in the presence of IM in K562-R cells (Figure 5b ), which are resistant to IM due to over-expression of Lyn (Donato et al., 2003 (Donato et al., , 2004 . We have not established that treatment of imatinib resistance cells with imatinib will alter the signaling pathway or change the effects of Jak2 inhibition. In studies carried out by others, PP2A and Jak2 are associated in mouse 32D cells (Yokoyama et al., 2001) , and studies by the Miller group (Yokoyama et al., 2003) suggest that Jak2 phosphorylates PP2A at tyrosine 307 of its catalytic subunit, making PP2A inactive. Increased phosphorylation of tyrosine 307 of PP2A was seen in Bcr-Abl þ cells over-expressing SET (Neviani et al., 2005) , suggesting that PP2A is regulated by both SET expression and tyrosine phosphorylation caused by Jak2, which makes PP2A functionally inactive. These results indicate that Jak2 modulates the SET-PP2A-Shp1 pathway by regulating both SET and PP2A. In this regard, Shp1 levels are increased on Jak2 inhibition TG-Jak2-I (0.5µM) /37.5% TG-Jak2-I (1.0µM) /53.5%
TG-Jak2-I (2µM) /71.1% TG-Jak2-I (2.5µM)/71.2% TG-Jak2-I (5µM)/83.2% D1 ( Figures 4a-c) , but we have not explored the mechanism by which Jak2 inhibition reduces SET leading to the increase of PP2A and Shp1 expression.
Our studies indicate that Lyn is downstream of Jak2 but upstream of Gab2 in BCR-ABL þ cells, as knockdown of Lyn strongly decreases pTyr Gab2 at the YxxM sequence ( Figure 2E ). This effect of Lyn kinase on Gab2 is observed in both IM-sensitive and -resistant cells as measured by YxxM phosphorylation of Gab2. These results suggest that Lyn either directly or indirectly causes the phosphorylation of YxxM of Gab2. Thus, the Bcr-Abl/Jak2/Lyn pathway will lead to activation of PI-3 kinase by interaction with the Bcr-Abl pTyr 177/ Grb2/Gab2 complex. Maintaining the activity of PI-3 kinase pathway is essential to help maintain the transformed phenotype of leukemia cells. PI-3 kinase maintains highly activated Akt, which prevents apoptosis in CML (Samanta et al., 2006) . We also note that Akt is dephosphorylated and thus inactivated by serine phosphatase PP2A (Li et al., 2003) , but PP2A remains in an inactive form in Bcr-Abl þ cells because of Jak2-induced expression of the PP2A inhibitor SET ( Figure 3A , panels a-e) (Li et al., 2003; Nawa et al., 2008) . Thus, Jak2 inhibition causes inactivation of Lyn kinase and activates PP2A-mediated dephosphorylation of Akt, which then leads to rapid induction of apoptosis in IM-sensitive and -resistant Bcr-Abl þ cells, including BaF3-Bcr-Abl mutant T315I and E255K cells. A model describing Jak2 inhibition and subsequent events leading to dephosphorylation of Lyn is presented in Figure 6 . Thus, employing such Jak2 inhibitors will be an excellent strategy to kill IM and dasatinib-resistant cells and also to manage CML patients in whom imatinib and dasatinib and other potent tyrosine kinase inhibitors are ineffective for the treatment of CML, including late stages of CML (blast crisis stages).
Materials and methods
Antibodies and drugs
Anti-phosphoSer 473-Akt (pAkt), anti-Akt, anti-Lyn (monoclonal and polyclonal), anti-Gab2 (goat), anti-GSK3, antipSer9 GSK3, c-Myc, SET and Jak2 antibodies conjugated with protein-A agarose were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against pJak2 (pTyr 1007/8), Jak1 (pTyr 1022/1023), Jak3 (pTyr 980), phospho-Src 416/pLyn (396), pLyn (Tyr507), pTyr 452 Gab2 (YxxM) and a-tubulin were obtained from Cell Signaling Technology (Beverley, MA, USA). Sodium stibagluconate (SSG) was purchased from Sigma Chemical Co. (St Louis, MO, USA). Kit for apoptosis measurement was purchased from B.D. Bioscience-Pharmingen (San Diego, CA, USA). AG490 was purchased from LC Laboratories, Woburn, MA, USA and 1,2,3,4,5.6-hexabromocyclohexane (HBC) was purchased from EMD Chemicals (San Diego, CA, USA). The TargeGen Jak2 inhibitor (TG101209) was supplied under a Material Transfer Agreement from TargeGen, Inc.
Immunoprecipitation and western blotting
Treated and untreated cells were harvested, lysed and processed as described (Samanta et al., 2006) .
Kinase assays
Jak2 kinase assay was carried out following the methods of Xie et al. (2001) and Sandberg et al. (2005) .
Apoptosis assays
Flow cytometry, using Annexin V/PI staining, was used to determine the level of late-stage apoptosis following the manufacturer's protocol.
Transfection of siRNA of signaling molecules (Jak2/Lyn) Short interfering RNA duplexes targeting human and mouse Jak2 and Lyn were designed and synthesized by Dharmacon and used as described (Ptasznik et al., 2004) . The human and mouse Jak2 siRNAs were specific to Jak2 and did not have sequence overlap with and did not knock down Jak1, Jak3 and Tyk2. For transfection of siRNA by electroporation, we followed the Nucleofection protocol of the manufacturer program # E032 (for Nucleofactor II, Amaxa Inc. Scientific Support, Walkersville, MD, USA). The cells were transfected and incubated for 72 h. Western blotting was performed as above.
PP2A activity assay PP2A activity assay was performed with cell lysates using a PP2A immunoprecipitation phosphatase assay kit (Upstate) as described (Neviani et al., 2005) .
Colony formation assay
Colony formation assay was carried out following the method described (Neviani et al., 2005) .
CML patient cells
Cells from CML and normal donors were obtained under an approved institutional protocol. CML cells were separated by centrifugation through Histopaque 1077 (Sigma) and the cells were suspended in RPMI medium with 10% fetal bovine serum (FBS).
